Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
Evaluating the efficacy and safety of post surgical Giredestrant compared with doctors choice of endocrine therapy (Tamoxifen, Anastrozole, Letrozole or Exemestane) in patients with estrogen receptor−positive, HER2-negative early breast cancer.
The Medical Oncology Clinical Research team, based within the Mater Cancer Care Centre, currently has 22 actively recruiting trials.
The purpose of this study is to investigate if a new treatment for breast cancer, known as gedatolisib, is safe and effective when combined with other drugs in the treatment of breast cancer that is advanced or that has spread to other parts of your body.
A potential new treatment for advanced ovarian, peritoneal or fallopian tube cancer.